Juniper's board has greater ratio of women than any other firm in Mass.

With a market value of less than $100 million, Boston-based Juniper Pharmaceuticals may not be one of the leading local biotechs in terms of size. But with a board appointment last week, it’s now a leader in the state around the diversity of its board of directors. Mary Ann Gray, former lead director of Dyax Corp. until its acquisition by Shire (Nasdaq: SHPG) earlier this year, was appointed to the seven-member board of Juniper (Nasdaq: JNP) on March 24. She replaces former director Donald Hunter,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news